title: Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
abstract: OBJECTIVE
  The aim of this study was to evaluate the treatment effect of diquafosol 3% with preservative-free sodium hyaluronate 0.1% eye drops in dry eye syndrome.
  
  
  METHODS
  In total, 150 patients with dry eye syndrome were divided randomly into 3 groups. Group 1 (50 patients) was treated 4 times daily with preserved sodium hyaluronate 0.1%, group 2 (50 patients) was treated 4 times daily with diquafosol 3%, and group 3 (50 patients) was treated 4 times daily with diquafosol 3% and preservative-free sodium hyaluronate 0.1% eye drops for 3 months. Ocular surface disease index (OSDI) score, tear film break-up time, Schirmer I test, corneal fluorescein staining, and impression cytology were evaluated.
  
  
  RESULTS
  There were significant improvements in the OSDI score, tear film break-up time, Schirmer I score, fluorescein and Rose Bengal staining, goblet cell density, and impression cytological findings in groups 2 and 3 compared with those for group 1 in patients with dry eye syndrome at 1, 2, and 3 months (P < 0.05). There were statistically significant improvements in the OSDI score (-8.48 ± 0.97, -5.69 ± 0.78; P = 0.02), fluorescein (-1.43 ± 0.21, -1.02 ± 0.18; P = 0.03), and Rose Bengal staining (-1.12 ± 0.26, -0.75 ± 0.12; P = 0.03), goblet cell density (89.65 ± 14.39, 70.36 ± 16.75; P = 0.03), and impression cytological findings (-0.53 ± 0.12, -0.34 ± 0.90; P = 0.01) in group 3 compared with those in group 2 at 3 months.
  
  
  CONCLUSIONS
  Treatment with diquafosol 3% with preservative-free sodium hyaluronate 0.1% was more effective than diquafosol 3% monotherapy or treatment with preserved sodium hyaluronate 0.1% in dry eye syndrome. Preservative-free sodium hyaluronate 0.1% eye drops can increase the effect of diquafosol 3% in dry eye syndrome.
authors: *Department of Ophthalmology, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Gangwon-Do, Korea; †Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea; and ‡Institute of Clinical Medicine Research, Bucheon St. Mary's Hospital, Bucheon, Gyunggi-Do, Korea.
authors: Ho Sik
authors: HS
authors: Hwang
authors: Yoon-Mi
authors: YM
authors: Sung
authors: Weon Sun
authors: WS
authors: Lee
authors: Eun Chul
authors: EC
authors: Kim
mesh_terms: D000368:Aged; D004338:Drug Combinations; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D019793:Fluorescein; D005456:Fluorescent Dyes; D015590:Fluorophotometry; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011122:Polyphosphates / Q000627:therapeutic use*; D011310:Preservatives, Pharmaceutical; D058912:Purinergic P2Y Receptor Agonists / Q000627:therapeutic use*; D012395:Rose Bengal; D013666:Tears / Q000737:chemistry; D014500:Uracil Nucleotides / Q000627:therapeutic use*; D055675:Viscosupplements / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D005456:Fluorescent Dyes; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D011310:Preservatives, Pharmaceutical; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; D055675:Viscosupplements; D012395:Rose Bengal; C403315:diquafosol; D006820:Hyaluronic Acid; D019793:Fluorescein